Ivermectin vs. Fenbendazole – a quick comparison
| Feature | Ivermectin | Fenbendazole |
|---------|-----------------|------------------|
| Drug class | Macrocyclic lactone | Benzimidazole (antimitotic) |
| Primary mechanism | Binds to glutamate‑gated chloride channels in parasite nerve/muscle cells → hyperpolarization → paralysis & death. | Binds β‑tubulin → inhibits microtubule polymerization → disrupts cell division and motility. |
| Spectrum (parasites) | Strongyloides, Onchocerca, Scabies, Lice, Threadworms, Hookworms, Giardia (some efficacy), Dirofilaria (heart‑worm in dogs), Toxocara, etc. | Roundworms (e.g., Ascaris, Trichuris, Ancylostoma, Toxocara), Hookworms, Tapeworms, Giardia (in animals). |
| Human approval (FDA) | Approved for strongyloidiasis, onchocerciasis, scabies, lice, threadworm (pinworm), and as an adjunct in certain veterinary protocols. | Not FDA‑approved for humans; marketed only for animals (dogs, cats, livestock, poultry). |
| Common human doses | 200 µg/kg orally (often a single dose or twice‑weekly for heart‑worm prevention in dogs; in humans, usually 1–2 mg/kg in one or two doses). | – (No standard human dose). |
| Common veterinary doses | 0.2 mg/kg orally or injectable; used for heart‑worm prevention (every 6–8 weeks). | 50–100 mg/kg orally for 3–5 days (dogs/cats); 25–50 mg/kg for larger livestock. |
| Pharmacokinetics | Lipophilic, high volume of distribution, long half‑life (~12–36 h in humans), metabolized mainly by CYP3A4. | Poor oral absorption; metabolized to active sulfone metabolites (e.g., fenbendazole sulfone) in many animals; short half‑life (~3–4 h in dogs). |
| Safety & side‑effects (humans) | Generally well‑tolerated; mild GI upset, dizziness, pruritus. Rare neurotoxicity in individuals with MDR1 mutations (not an issue in humans). | Limited data; when used off‑label, reports of nausea, vomiting, headache. |
| Safety & side‑effects (animals) | Mild GI upset, itching. In cattle with MDR1 mutations → neurotoxicity (lameness). | GI upset, vomiting, diarrhea; rare hypersensitivity. |
| Drug interactions | CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin) can alter levels. | Minimal interaction data; some CYP interactions noted in dogs. |
| Resistance | Parasite resistance emerging in some regions (e.g., heart‑worm). | Resistance noted in livestock (e.g., Haemonchus contortus) but less common in pets. |
| Off‑label / research uses | Studied for COVID‑19, malaria, some cancers – none proven clinically useful. | Studied for cancer (e.g., glioblastoma, pancreatic cancer) and malaria – experimental only. |
| Formulations | Oral tablets, oral solution, injectable, topical creams/shampoos (for scabies). | Oral tablets, chewable tablets, liquid, paste (for animals). |
Bottom line
- Ivermectin is a well‑established, FDA‑approved antiparasitic for humans and widely used in veterinary medicine. Its action is on nervous‑system chloride channels, giving it a broad spectrum against many nematodes, ectoparasites, and some protozoa.
- Fenbendazole is a benzimidazole antimitotic mainly used in animals. It disrupts microtubules and is effective against many gastrointestinal nematodes and tapeworms, but it has no regulatory approval for human use.
Because they belong to different chemical families, they have different pharmacokinetics, safety profiles, and clinical indications. If you’re considering either drug for a particular parasite, consult a qualified healthcare or veterinary professional to confirm the correct drug, dose, and duration for your species and situation.